Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL.
Tseng YD, et al. Among authors: hu jc.
J Urol. 2012 Jun;187(6):2068-73. doi: 10.1016/j.juro.2012.01.073. Epub 2012 Apr 11.
J Urol. 2012.
PMID: 22498212
Clinical Trial.